顺式-4-氨基-四氢呋喃-3-醇 | 535936-61-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 中文名称: 顺式-4-氨基-四氢呋喃-3-醇
• 英文名称: (3S,4S)-4-aminotetrahydrofuran-3-ol
• 英文别名: (3S,4S)-4-aminooxolan-3-ol
• CAS: 535936-61-9
• 化学式: C₄H₉NO₂
• 分子量: 103.121
• InChiKey: HQVKXDYSIGDGSY-IUYQGCFVSA-N

物化性质

• 沸点：
  231.7±40.0 °C(Predicted)
• 密度：
  1.222±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  55.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  溴甲苯 、 顺式-4-氨基-四氢呋喃-3-醇 在 四丁基溴化铵 、 potassium carbonate 作用下， 以 乙腈 为溶剂， 以92 %的产率得到(3S,4S)-4-(dibenzylamino)oxolan-3-ol
  参考文献：
  名称：

  THIADIAZOLE DERIVATIVES AS INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF

  摘要：

  The present disclosure relates to compounds of Formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein Ring A, R1, R2, R3, R4, and m are described herein, methods of preparation, methods of treatment, and pharmaceutical compositions comprising same. The present disclosure further relates to the use of the compounds of Formula (I), and pharmaceutically acceptable salts thereof, in the treatment of cGAS-related diseases and disorders.

  公开号：

  WO2024137607A1
• 作为产物：
  描述：

  (3S,4S)-3-tert-butoxycarbonylamino-4-hydroxytetrahydrofuran 在 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 24.0h， 以50%的产率得到顺式-4-氨基-四氢呋喃-3-醇
  参考文献：
  名称：

  Enzymatic preparation of cis and trans-3-amino-4-hydroxytetrahydrofurans and cis-3-amino-4-hydroxypyrrolidines

  摘要：

  The lipase catalyzed resolution of cis and trans-3-amino-4-hydroxytetrahydraurans and cis-3-amino-4-hydroxypyrrolidines have been studied. For all the heterocycles, the best enantioselectivity was obtained using Candida antarctica lipases A and B as catalysts in hydrolytic processes. The absolute configuration of the optically pure obtained heterocycles has been assigned. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.05.014

文献信息

• [EN] HETEROARYLAMIDE INHIBITORS OF TBK1<br/>[FR] INHIBITEURS HÉTÉROARYLAMIDE DE TBK1
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2015134171A1

  公开（公告）日：2015-09-11

  The present invention provides compounds of formula 1: which are useful as inhibitors of TBK-1, pharmaceutical compositions thereof, methods for treatment of conditions associated with TBK1, processes for making the compounds and intermediates thereof.

  本发明提供了化合物的公式1：这些化合物可用作TBK-1的抑制剂，以及与之相关的药物组合物、治疗与TBK1相关疾病的方法、制备这些化合物及其中间体的工艺。
• [EN] SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS<br/>[FR] DÉRIVÉS DE SULPHAMOYLARYLE ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS POUR LE TRAITEMENT DE LA FIBROSE HÉPATIQUE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018145620A1

  公开（公告）日：2018-08-16

  Potent 5-HT2B antagonist of Formula (A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof and their use wherein R1 to R4 and Ar have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them, alone or in combination with other drugs, in fibrosis and/or cirrhosis prevention or therapy.

  强效的Formula（A）的5-HT2B拮抗剂，包括立体化异构形式，以及其盐、水合物、溶剂合物及其用途，其中R1至R4和Ar的含义如本文所定义。本发明还涉及制备所述化合物的方法，含有它们的药物组合物，单独或与其他药物联合在纤维化和/或肝硬化预防或治疗中的用途。
• Synthesis of novel, optically active, heterocyclic amino alcohols through desymmetrization of a C2-symmetric cyclic sulfate
  作者：B.Moon Kim、Sung Jin Bae、Gunn Seomoon

  DOI：10.1016/s0040-4039(98)01453-1

  日期：1998.9

  A general and efficient method for the synthesis of optically active cis-4-amino-3-hydroxy-substituted heterocycles (1–4) has been developed through desymmetrization of a C2-symmetric cyclic sulfate chiron prepared from catalytic asymmetric dihydroxylation of 1,4-dichloro-trans-2-butene.

  通过对由1的催化不对称二羟基化反应制备的C 2对称环状硫酸盐Chiron脱对称化，已开发出一种通用且有效的合成光学活性顺式-4-氨基-3-羟基取代的杂环（1-4）的方法。 4-二氯反式-2-丁烯。
• Substituted aryl 1, 4-pyrazine derivatives
  申请人：Verhoest R. Patrick

  公开号：US20050049257A1

  公开（公告）日：2005-03-03

  Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.

  本发明揭示了替代芳基1,4-吡嗪衍生物及其在治疗焦虑症、抑郁症和与压力相关的疾病中的应用。
• Substituted aryl 1,4-pyrazine derivatives
  申请人：——

  公开号：US20030144297A1

  公开（公告）日：2003-07-31

  Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.

  本发明揭示了用于治疗焦虑症、抑郁症和与压力相关的疾病的取代芳基1,4-吡嗪衍生物及其使用。